“…More than 85% of germline APC mutations in patients with CMTC have been detected in exon 15 (codons 463 to 1,387), in the same genomic location usually associated with CHRPE ( 39 ). This area also includes a hotspot (codon 1,061) for CMTC and hepatoblastoma ( 25 , 35 , 37 , 39 ), but mutations in codons 140, 159, 161, 213, 278, 302, 313, 325, 332, 418, 471, 499, 554, 578, 582, 593, 625, 654, 698, 704, 737, 769, 778, 804, 834, 848, 935, 937, 938, 964, 976, 977, 979, 993, 1,062, 1,068, 1,073, 1,105, 1,110, 1,157, 1,275, 1,307, 1,309, 1,394, 1,465 and 2,092 have also been described ( 33 , 56 , 75 , 76 ). When comparing the prevalence of APC mutations in patients with FAP and TC in relation to the prevalence of such mutations in unselected individuals with FAP, a higher risk of CMTC exists in the population harboring APC mutations proximal to the 5′ end (proximal to codon 528) as well as in the established high-risk group with mutation at codon 1,061 ( 75 ).…”